The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.

New Alfa Romeo Stelvio SUV may be set to get petrol power after all New Alfa Romeo Stelvio SUV may be set to get petrol power after all Alfa’s large SUV is still on track, but the outgoing boss ...

Lava Iris Alfa mobile was launched in January 2015. The phone comes with a 5.00-inch touchscreen display offering a resolution of 480x854 pixels. Lava Iris Alfa is powered by a 1.2GHz quad-core ...

President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...

That said, due to the current flaccid demand from retail customers for electric cars, Alfa will also bring a petrol Ibrida (that’s Italian for hybrid) version to the UK in mid-2025 ...

That's because it recently received FDA Breakthrough Therapy Designation [BTD] for tividenofusp alfa [DNL310] for the treatment of patients with Hunter Syndrome [also known as MPS II]. Even better ...

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with ...

Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 ...